2017
DOI: 10.4103/heartviews.heartviews_6_17
|View full text |Cite
|
Sign up to set email alerts
|

Tacrolimus as a rare cause of pericardial effusion in a renal transplant recipient

Abstract: Pericardial effusion in a renal transplant recipient represents a diagnostic conundrum with a variety of differential diagnoses. Immunosuppressive medications such as sirolimus have been linked to pericardial effusions in the reported literature. Tacrolimus has been reported to be associated with pleural effusions and ascites. We present a case of a patient with tacrolimus as the likely cause of a recurrent pericardial effusion.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(10 citation statements)
references
References 6 publications
0
10
0
Order By: Relevance
“…Other than metabolic derangements, CNIs may be associated with direct cardiac toxicity, including dilated cardiomyopathy, hypertrophic cardiomyopathy, and pericardial effusions, as documented by several case reports and small series 107-112 ; however, because of superior efficacy over alternatives, the CNIs remain part of the first-line immunosuppressive regimen, even among heart transplant recipients. 113…”
Section: Risk Factors Of Cvd In Ktrsmentioning
confidence: 99%
See 1 more Smart Citation
“…Other than metabolic derangements, CNIs may be associated with direct cardiac toxicity, including dilated cardiomyopathy, hypertrophic cardiomyopathy, and pericardial effusions, as documented by several case reports and small series 107-112 ; however, because of superior efficacy over alternatives, the CNIs remain part of the first-line immunosuppressive regimen, even among heart transplant recipients. 113…”
Section: Risk Factors Of Cvd In Ktrsmentioning
confidence: 99%
“…18,104 Unfortunately, this appears to be more common with tacrolimus-based regimens because of the additional tacrolimus-related effect on pancreatic glucokinase activity and is a significant issue associated with the use of this agent. 105,106 Other than metabolic derangements, CNIs may be associated with direct cardiac toxicity, including dilated cardiomyopathy, hypertrophic cardiomyopathy, and pericardial effusions, as documented by several case reports and small series [107][108][109][110][111][112] ; however, because of superior efficacy over alternatives, the CNIs remain part of the first-line immunosuppressive regimen, even among heart transplant recipients. 113…”
Section: Cnis and Metabolic Derangementsmentioning
confidence: 99%
“…It is worth mentioning that tacrolimus may also cause pericardial effusion as recently reported 10. Though tacrolimus and sirolimus bind to the same FK12 protein, the binding sites and downstream pathways are different 11.…”
Section: Discussionmentioning
confidence: 80%
“…5 It is proposed that tacrolimus can cause serosal inflammation that leads to fluid accumulation. [1][2][3][4][5] To the best of our knowledge, there is no report about ascites resulting from long-term tacrolimus treatment. In our patient, we tried all the traditional diagnostic and treatment methods for diagnosis in a patient with ascites.…”
Section: Discussionmentioning
confidence: 99%
“…Pleural effusion, pericardial effusion, and ascites have been reported to be related with tacrolimus in very few cases. [1][2][3][4] Herein, we report a case of unexplained massive fluid retention with ascites in the late post-transplant period and showed dramatic improvement on conversion to cyclosporine.…”
Section: Introductionmentioning
confidence: 99%